Glycopeptide antibiotics and their novel semi-synthetic derivatives

Current Pharmaceutical Biotechnology

Volumn 12, Issue 8, 2011, Pages 1194-1204

  Jeya, Marimuthu ^a   Moon, Hee Jung ^a   Lee, Kyoung Mi ^a   Kim, In Won ^a   Lee, Jung Kul ^a  

^a Konkuk University   (South Korea)

Author keywords

Dalbavancin; Glycopeptides; Oritavancin; Semisynthetic derivatives; Teicoplanin; Telavancin; Vancomycin

Indexed keywords

AVOPARCIN; BALHIMYCIN; CHLOROORIENTICIN A; COMPLESTATIN; DALBAVANCIN; DECHLOROBALHIMYCIN V; DECHLOROEREMOMYCIN; EREMOMYCIN; HEPTAPEPTIDE; LINEZOLID; MANNOPEPTIMYCIN; MANNOPEPTIN; METHYLBALHIMYCIN; N DEMETHYLBALHIMYCIN; NORVANCOMYCIN; ORITAVANCIN; POLYPEPTIDE ANTIBIOTIC AGENT; RISTOCETIN; TEICOPLANIN; TELAVANCIN; UNCLASSIFIED DRUG; VANCOMYCIN; VANCOMYCIN AGLYCON;

ANTIBACTERIAL ACTIVITY; ANTIBIOTIC RESISTANCE; ANTIVIRAL ACTIVITY; CLINICAL TRIAL (TOPIC); CROSS LINKING; DRUG FEVER; DRUG HALF LIFE; DRUG INDUCED HEADACHE; DRUG MECHANISM; DRUG STRUCTURE; DRUG SULFATION; DRUG SYNTHESIS; HALOGENATION; HUMAN; NAUSEA; NEPHROTOXICITY; NONHUMAN; OTOTOXICITY; PEPTIDE SYNTHESIS; RED MAN SYNDROME; REVIEW; TOXICOLOGY;

ANTI-BACTERIAL AGENTS; DRUG RESISTANCE, BACTERIAL; GLYCOPEPTIDES; STRUCTURE-ACTIVITY RELATIONSHIP;

POSIBACTERIA;

EID: 79960002430     PISSN: 13892010     EISSN: 18734316     Source Type: Journal    
DOI: 10.2174/138920111796117382     Document Type: Review

References (117)

1. Ward, T.J.; Oswald, T.M. Enantioselectivity in capillary electrophoresisusing the macrocyclic antibiotics. J. Chromatogr. A, 1997,792(1), 309-325.
2. Sosio, M.; Stinchi, S.; Beltrametti, F.; Lazzarini, A.; Donadio, S. The gene cluster for the biosynthesis of the glycopeptide antibioticA40926 by Nonomuraea species. Chem. Biol., 2003, 10(6), 541-549.
3. Barna, J.C.J.; Williams, D.H.; Stone, D.J.M.; Leung, T.W.C.; Doddrell, D.M. Structure elucidation of the teicoplanin antibiotics. J. Am. Chem. Soc., 1984, 106(17), 4895-4902
4. Walsh, C.; Freel Meyers, C.L.; Losey, H.C. Antibiotic glycosyl transferases: Antibiotic maturation and prospects for reprogramming.J. Med. Chem., 2003, 46(16), 3425-3436.
5. Kunstmann, M.P.; Mitscher, L.A.; Porter, J.N.; Shay, A.J.; Darken, M.A. LL-AV290, a new antibiotic. I. Fermentation, isolation, andcharacterization. Antimicrob. Agents Chemother., 1968, 8, 242-245.
6. Vertesy, L.; Fehlhaber, H.W.; Kogler, H.; Limbert, M. New 4-oxovancosamine-containing glycopeptide antibiotics from Amycolatopsissp. Y-86, 21022. J. Antibiot., 1996, 49(1), 115-118.
7. Fasola, E.L.; Moody, J.A.; Gerding, D.N.; Peterson, L.R. In vitroactivity of LY 264826 compared with that of vancomycin against100 clinical isolates each of methicillin-resistant Staphylococcusaureus and Clostridium difficile. Antimicrob. Agents Chemother.,1990, 34(10), 2007-2008.
8. Hunt, A.H.; Marconi, G.G.; Elzey, T.K.; Hoehn, M.M. A51568A:N-demethylvancomycin. J. Antibiot., 1984, 37(8), 917-919.
9. Gause, G.F.; Brazhnikova, M.G.; Lomakina, N.N.; Goldberg, L.E.; Laiko, A.V. Eremomycin-a new antibiotic of the polycyclic glycopeptidegroup. Antibiot. Khimioter., 1989, 34(5), 348-352.
10. Hayashi, T.; Harada, Y.; Ando, K. Isolation and characterization ofmannopeptins, new antibiotics. J. Antibiot., 1975, 28(7), 503-507.
11. Grundy, W.E.; Sinclair, A.C.; Theriault, R.J.; Goldstein, A.W.; Rickher, C.J.; Warren, H.B. Jr., Oliver, T.J.; Sylvester, J.C. Ristocetin, microbiologic properties. Antibiot. Annu., 1956, 687-692.
12. Parenti, F.; Beretta, G.; Berti, M.; Arioli, V. Teichomycins, newantibiotics from Actinoplanes teichomyceticus Nov. Sp. I. Descriptionof the producer strain, fermentation studies and biologicalproperties. J. Antibiot., 1978, 31(4), 276-283.
13. McCormick, M.H.; McGuire, J.M.; Pittenger, G.E.; Pittenger, R.C.; Stark, W.M. Vancomycin, a new antibiotic. I. Chemical and biologicproperties. Antibiot. Annu., 1955, 3, 606-611.
14. Nicolaou, K.C.; Boddy, C.N.; Brase, S.; Winssinger, N. Chemistry,biology, and medicine of the glycopeptide antibiotics. Angew.Chem. Int. Ed. Engl., 1999, 38(15), 2096-2152.
15. Pootoolal, J.; Neu, J.; Wright, G.D. Glycopeptide antibiotic resistance.Annu. Rev. Pharmacol. Toxicol., 2002, 42, 381-408.
16. Nieto, M.; Perkins, H.R. Modifications of the acyl-D-alanyl-Dalanineterminus affecting complex-formation with vancomycin.Biochem. J., 1971, 123(5), 789-803.
17. Ge, M.; Chen, Z.; Onishi, H.R.; Kohler, J., Silver L.L, Kerns, R.; Fukuzawa, S.; Thompson, C.; Kahne, D. Vancomycin derivatives that inhibit peptidoglycan biosynthesis without binding D-Ala-DAla. Science, 1999, 284(5413), 507-511.
18. Hubbard, B.K.; Thomas, M.G.; Walsh, C.T. Biosynthesis of L-phydroxyphenylglycine,a non-proteinogenic amino acid constituentof peptide antibiotics. Chem. Biol., 2000, 7(12), 931-942.
19. Li, T.L.; Choroba, O.W.; Charles, E.H.; Sandercock, A.M.; Williams, D.H.; Spencer, J.B. Characterisation of a hydroxymandelateoxidase involved in the biosynthesis of two unusual amino acidsoccurring in the vancomycin group of antibiotics. Chem. Commun.,2001, 18, 1752-1753.
20. Li, T.L.; Haung, F.; Haydock, S.F.; Mironenko, T.; Leadlay, P.F.; Spencer, J.B. The biosynthetic gene cluster for the glycopeptide antibioticteicoplanin in Actionplanes teichomyceticus: identificationof the glycosyltransferases and of a key acyltransferase involved inthe maturation of the antibiotic. Chem. Biol., 2004, 11(1), 107-119.
21. Chen, D.K.; Pearce, L.; McGeer, A.; Low, D.E.; Willey, B.M. Evaluation of D-xylose and 1% methyl-alpha-D-glucopyranosidefermentation tests for distinguishing Enterococcus gallinarum fromEnterococcus faecium. J. Clin. Microbiol., 2000, 38(10), 3652-3655.
22. Pfeifer, V.; Nicholson, G.; Ries, J.; Recktenwald, J.; Schefer, A.; Shawky, R.; Schröder, J.; Wohlleben, W.; Pelzer, S. A polyketidesynthase in glycopeptide biosynthesis: the biosynthesis of the nonproteinogenicamino acid (S)-3,5-dihydroxyphenylglycine. J. Biol.Chem., 2001, 276(42), 38370-38377.
23. Sosio, M.; Kloosterman, H.; Bianchi, A.; de Vreugd, P.; Dijkhuizen, L.; Donadio, S. Organization of the teicoplanin genecluster in Actinoplanes teichomyceticus. Microbiology, 2004, 150,95-102.
24. Kahne, D.; Leimkuhler, C.; Lu, W.; Walsh, C. Glycopeptide andlipoglycopeptide antibiotics. Chem. Rev., 2005, 105(2), 425-448.
25. Marahiel, M.A.; Stachelhaus, T.; Mootz, H.D. Modular peptidesynthetases involved in nonribosomal peptide synthesis. Chem.Rev., 1997, 97(7), 2651-2674.
26. Mootz, H.D.; Schwarzer, D.; Marahiel, M.A. Ways of assemblingcomplex natural products on modular nonribosomal peptide synthetases.Chembiochem., 2002, 3(6), 490-504.
27. Sosio, M.; Donadio, S. Understanding and manipulating glycopeptidepathways: the example of the dalbavancin precursor A40926.J. Ind. Microbiol. Biotechnol., 2006, 33(9), 569-576.
28. Bischoff, D.; Pelzer, S.; Bister, B.; Nicholson, G.J.; Stockert, S.; Schirle, M.; Wohlleben, W.; Jung, G.; Sussmuth, R.D. The biosynthesisof vancomycin-type glycopeptide antibiotics-The order ofthe cyclization steps. Angew. Chem. Int. Ed. Engl., 2001, 40(24),4688-4691.
29. Hadatsch, B.; Butz, D.; Schmiederer, T.; Steudle, J.; Wohlleben, W.; Sussmuth, R.; Stegmann, E. The biosynthesis of teicoplanintypeglycopeptide antibiotics: assignment of p450 monooxygenasesto side chain cyclizations of glycopeptide a47934. Chem. Biol., 2007, 14(9), 1078-1089.
30. Malabarba, A.; Strazzolini, P.; Depaoli, A.; Landi, M.; Berti, M.; Cavalleri, B. Teicoplanin, antibiotics from Actinoplanes teichomyceticusnov. sp. VI. Chemical degradation: physico-chemical andbiological properties of acid hydrolysis products. J. Antibiot., 1984,37(9), 988-999.
31. Malabarba, A.; Nicas, T.I.; Thompson, R.C. Structural modifications of glycopeptide antibiotics. Med.Res. Rev., 1997, 17(1), 69-137.
32. Truman, A.W.; Robinson, L.; Spencer, J.B. Identification of adeacetylase involved in the maturation of teicoplanin. Chembiochem.,2006, 7(11), 1670-1675.
33. Serina, S.; Radice, F.; Maffioli, S.; Donadio, S.; Sosio, M. Glycopeptideresistance determinants from the teicoplanin producerActinoplanes teichomyceticus. FEMS Microbiol. Lett., 2004,240(1), 69-74.
34. Perkins, H. R. Vancomycin and related antibiotics. Pharmacol Ther., 1982, 16(2), 181-197.
35. Boger, D.L. Vancomycin, teicoplanin, and ramoplanin: syntheticand mechanistic studies. Med. Res. Rev., 2001, 21(5), 356-381.
36. Kirst, H.A.; Thompson, D.G.; Nicas, T.I. Historical yearly usage ofvancomycin. Antimicrob. Agents. Chemother., 1998, 42(5), 1303-1304.
37. Parenti, F. Glycopeptide antibiotics. J. Clin. Pharmacol., 1988,28(2), 136-140.
38. Borghi, A.; Coronelli, C.; Faniuolo, L.; Allievi G.; Pallanza, R.; Gallo, G.G. Teichomycins, new antibiotics from Actinoplanesteichomyceticus nov. sp. IV. Separation and characterization of thecomponents of teichomycin (teicoplanin). J. Antibiot., 1984, 37(6),615-620.
39. Borghi, A.; Antonini, P.; Zanol, M.; Ferrari, P.; Zerilli, L.F.; Lancini, G.C. Isolation and structure determination of two new analogsof teicoplanin, a glycopeptide antibiotic. J. Antibiot., 1989, 42(3),361-366.
40. Cometti, A., Gallo, G.G.; Kettenring, J.; Panzone, G.B.; Tuan, G.; Zerilli, L.F. Isolation and structure determination of the main relatedsubstances of teicoplanin, a glycopeptide antibiotic. FormacoScience, 1988, 43(5), 1005-1018.
41. Heydorn, A.; Suhr-Jessen, T.; Nielsen, J. Growth and production kinetics of a teicoplanin producing strain of Actinoplanes teichomyceticus. J. Antibiot., 1999, 52(1), 40-44.
42. Wood, M.J. The comparative efficacy and safety of teicoplanin and vancomycin. J. Antimicrob. Chemother., 1996, 37(2), 209-222. Erratumin: J. Antimicrob. Chemother., 1996, 38(5), 919. J. Antimicrob. Chemother., 1997, 40(1), 147.
43. Murphy, S.; Pinney, R.J. Teicoplanin or vancomycin in the treatmentof gram-positive infections? J. Clin. Pharm. Ther., 1995,20(1), 5-11.
44. Wilhelm, M.P.; Estes, L. Symposium on antimicrobial agents--PartXII. Vancomycin. Mayo. Clin Proc., 1999, 74(9), 928.
45. Ducharme, M.P.; Slaughter, R.L.; Edwards, D.J. Vancomycin pharmacokinetics in a patient population: effect of age, gender, and body weight. Ther. Drug. Monit., 1994, 16(5), 513-518.
46. Begg, E.J.; Barclay, M.L.; Kirkpatrick, C.J.M. The therapeuticmonitoring of antimicrobial agents. Br. J. Clin. Pharmacol., 1999,47(1), 23-30.
47. Hoeprich, P.D.; Jordan, M.C.; Ronald, A.R. Glycopeptides. In: Infectious Diseases: a treatise of infectious processes., 5th ed.;Hoeprich, P.D.; Jordan, M.C.; Ronald, A.R., Eds.; Lippincott,Philadelphia, 1994; pp. 256-258.
48. Kayaalp, S.O. Narrow Spectrum Antistaphylococcus and AntianaerobicDrugs and Polypeptidic Antibiotics. In: Medical Pharmacologyfrom the Rational Therapy Perspective. Kayaalp, S.O. Ed.Feryal; Ankara, 2002; pp. 280-93.
49. Rodriguez-Bano J. Selection of empiric therapy in patients withcatheter-related infections. Clin. Microbiol. Infect., 2002, 8(5), 275-281.
50. Erjavec, Z.; de Vries-Hospers, H.G.; Laseur, M.; Halie, R.M.; Daenen, S. A prospective, randomized, double-blinded, placebocontrolledtrial of empirical teicoplanin in febrile neutropenia withpersistent fever after imipenem monotherapy. J. Antimicrob. Chemother.,2000, 45(6), 843-849.
51. De Lalla, F. and Tramarin, A. A risk-benefit assessment of teicoplaninin the treatment of infections. Drug Saf., 1995, 13(5), 317-328.
52. Rubinstein, E. Cost implications of home care on serious infections.Hosp, Formul., 1993, 26:46-50.
53. Darley, E.S.R.; MacGowan, A.P. The use and therapeutic drugmonitoring of teicoplanin in the UK. Clin. Microbiol. Infect., 2004,10(1), 62-69.
54. Sahai, J.; Healy, D.P.; Shelton, M.J.; Miller, J.S.; Ruberg, S.J.; Polk, R. Comparison of vancomycin- and teicoplanin-induced histaminerelease and red man syndrome. Antimicrob. Agents. Chemother.,1990, 34(5), 765-769.
55. Sancar, A.; Yegenoglu, S.; de Vries, R.; Postma, M.; Simsek, N.; Pechlivanoglou, P.; Unal, S. Vancomycin vs teicoplanin in thetreatment of Gram-positive infections: a pharmacoeconomic analysisin a Turkish University Hospital. Pharm World Science, 2008,30(6), 916-923.
56. Arthur, M.; Courvalin, P. Genetics and mechanisms of glycopeptideresistance in enterococci. Antimicrob. Agents. Chemother.,1993, 37(8),1563-1571.
57. Evers, S.; Quintiliani, R. Jr.; Courvalin, P. Genetics of glycopeptideresistance in enterococci. Microb. Drug. Resist., 1996, 2(2), 219-223.
58. Arthur, M.; Reynolds, P.; Courvalin, P. Glycopeptide resistance inenterococci. Trends. Microbiol., 1996, 4(10), 401-407.
59. Reynolds, P.E.; Courvalin, P, Vancomycin resistance in enterococcidue to synthesis of precursors terminating in D-alanyl-Dserine.Antimicrob. Agents. Chemother., 2005, 49(1), 21-25.
60. Arthur, M.; Reynolds, P.E.; Depardieu, F.; Ever, S.; Dutka-Malen, S.; Quintiliani, R.; Courvalin, P. Mechanisms of glycopeptide resistancein enterococci. J. Infect., 1996, 32(1), 11-16.
61. Fines, M.; Perichon, B.; Reynolds, P.; Sahm, D.F.; Courvalin, P. VanE, a new type of acquired glycopeptide resistance in Enterococcusfaecalis BM4405. Antimicrob. Agents. Chemother., 1999,43(9), 2161-2164.
62. Gholizadeh, Y.; Courvalin, P. Acquired and intrinsic glycopeptideresistance in enterococci. Int. J. Antimicrob. Agents., 2000,16(Suppl 1), S11-S17.
63. Arthur, M.; Depardieu, F.; Reynolds, P.; Courvalin, P. Quantitativeanalysis of the metabolism of soluble cytoplasmic peptidoglycan precursors of glycopeptide-resistant enterococci. Mol. Microbiol.,1996, 21(1), 33-44.
64. Bugg, T.D.; Wright, G.D.; Dutka-Malen, S.; Arthur, M.; Courvalin, P.; Walsh, C.T. Molecular basis for vancomycin resistance in Enterococcusfaecium BM4147: biosynthesis of a depsipeptide peptidoglycanprecursor by vancomycin resistance proteins VanH andVanA. Biochemistry, 1991, 30(43), 10408-10415.
65. Hiramatsu, K. Vancomycin resistance in Staphylococci. Drug Resist.Updates, 1998, 1, 135-150.
66. Cui, L.; Murakami, H.; Kuwahara-Arai, K.; Hanaki, H.; Hiramatsu, K. Contribution of a thickened cell wall and its glutamine nonamidatedcomponent to the vancomycin resistance expressed byStaphylococcus aureus Mu50. Antimicrob. Agents. Chemother.,2000, 44(9), 2276-2285.
67. Hanaki, H.; Kuwahara-Arai, K.; Boyle-Vavra, S.; Daum, R.S.; Labischinski, H.; Hiramatsu, K. Activated cell-wall synthesis is associatedwith vancomycin resistance in methicillin-resistantStaphylococcus aureus clinical strains Mu3 and Mu50. J. Antimicrob.Chemother., 1998, 42(2), 199-209.
68. Sieradzki, K.; Tomasz, A. Inhibition of cell wall turnover andautolysis by vancomycin in a highly vancomycin-resistant mutantof Staphylococcus aureus. J. Bacteriol., 1997, 179(8), 2557-2566.
69. Sieradzki, K.; Pinho, M.; Tomasz, A. Inactivated pbp4 in highlyglycopeptide-resistant laboratory mutants of Staphylococcusaureus. J. Biol. Chem., 1999, 274(27), 18942-18946.
70. Noble, W.C.; Virani, Z.; Cree, R.G. Co-transfer of vancomycin andother resistance genes from Enterococcus faecalis NCTC 12201 toStaphylococcus aureus. FEMS Microbiol. Lett., 1992, 72(2), 195-198.
71. Sievert, D.M.; Boulton, M.L.; Stolman, G.; Johnson, D.; Stobierski, M.G.; Downes, F.P.; Somsel, P.A.; Rudrik, J.T.; Brown, W.J.; Hafeez, W.; Lundstrom, T.; Flanagan, E.; Johnson, R.; Mitchell, J.; Chang, S. Staphylococcus aureus resistant to vancomycin. MMWRMorb. Mortal, Wkly Rep., 2002, 51(26), 565-567.
72. Allen, N.E.; Nicas, T.I. Mechanism of action of oritavancin andrelated glycopeptide antibiotics. FEMS Microbiol. Rev., 2003,26(5), 511-532.
73. Hancock, R.E.; Farmer, S.W. Mechanism of uptake of deglucoteicoplaninamide derivatives across outer membranes of Escherichiacoli and Pseudomonas aeruginosa. Antimicrob. Agents. Chemother.,1993, 37(3), 453-456.
74. Beauregard, D.A.; Williams, D.H.; Gwynn, M.N.; Knowles, D.J. Dimerization and membrane anchors in extracellular targeting ofvancomycin group antibiotics. Antimicrob. Agents. Chemother.,1995, 39(3), 781-785.
75. Dong, S.D.; Oberthur, M.; Losey, H.C.; Anderson, J.W.; Eggert, U.S.; Peczuh, M.W.; Walsh, C.T.; Kahne, D. The structural basis for induction of VanB resistance. J. Am. Chem. Soc., 2002,124(31), 9064-9065.
76. Thorson, J.S.; Hoster, T.J.; Jiang, J.; Biggins, J.B.; Ahlert, J. Nature's carbohydrate chemists: the enzymatic glycosylation of bioactive bacterial metabolites. Curr. Org. Chem. 2001, 5(2), 139-167.
77. Kirschning, A.; Bechthold, A. F.W.; Rohr, J. Chemical and biochemical aspects of deoxysugars and deoxysugar oligos accharides.Top. Curr. Chem., 1997, 188, 1-84.
78. Liu, H. W.; Thorson, J. S. Pathways and mechanisms in the biogenesis of novel deoxysugars by bacteria. Annu. Rev. Microbiol.,1994, 48, 223-256.
79. Mootz, H. D.; Marahiel, M. A. Biosynthetic systems for nonribosomal peptide antibiotic assembly. Curr. Opin. Chem. Biol., 1997,1(4), 543-551.
80. Solenberg, P. J.; Matsushima, P.; Stack, D. R.; Wilkie, S. C.; Thompson, R. C.; Baltz, R. H. Production of hybrid glycopeptide antibiotics in vitro and in Streptomyces toyocaensis. Chem. Biol.,1997, 4(3), 195-202.
81. Losey, H.C.; Jiang, J.; Biggins, J.B.; Oberthur, M.; Ye, X.Y.; Dong, S.D.; Kahne, D.; Thorson, J.S.; Walsh, C.T. Incorporation of glucose analogs by GtfE and GtfD from the vancomycin biosynthetic pathway to generate variant glycopeptides. Chem. Biol.,2002, 9(12), 1305-1314.
82. Bister, B.; Bischoff, D.; Nicholson, G.J.; Stockert, S.; Wink, J.; Brunati, C.; Donadio, S.; Pelzer, S.; Wohlleben, W.; Sussmuth, R.D. Bromobalhimycin and chlorobromobalhimycins-illuminatingthe potential of halogenases in glycopeptide antibiotic biosyntheses. Chembiochem., 2003, 4(7), 658-662.
83. Baltz, R.H. Molecular engineering approaches to peptide,polyketide and other antibiotics. Nat. Biotechnol., 2006, 24(12),1533-1540.
84. Puk, O.; Huber, P.; Bischoff, D.; Recktenwald, J.; Jung, G.; Sussmuth, R.D.; van Pee, K.H.; Wohlleben, W.; Pelzer, S. Glycopeptidebiosynthesis in Amycolatopsis mediterranei DSM5908: function ofa halogenase and a haloperoxidase/perhydrolase. Chem. Biol.,2002, 9(2), 225-235.
85. Stegmann, E.; Bischoff, D.; Kittel, C.; Pelzer, S.; Puk, O.; Recktenwald, J.; Weist, S.; Sussmuth, R.; Wohlleben, W. Precursordirectedbiosynthesis for the generation of novel glycopetides. Ernst Schering Res. Found. Workshop., 2005, (51), 215-232.
86. Van Bambeke, F. Glycopeptides in clinical development: pharmacological profile and clinical perspectives. Curr. Opin. Pharmacol.,2004, 4(5), 471-478.
87. Barrett, J.F. Oritavancin (Eli Lilly & Co). Curr. Opin. Investigat.Drugs., 2001, 2(8), 1039-1044.
88. Mercier, R.C.; Hrebickova, L. Oritavancin: a new avenue for resistant Gram-positive bacteria. Expert Rev. Anti-Infect. Ther., 2005,3(3), 325-332.
89. Allen, N.E.; Hobbs Jr., J.N.; Nicas, T.I. Inhibition of peptidoglycanbiosynthesis in vancomycin-susceptible and -resistant bacteria by asemisynthetic glycopeptide antibiotic. Antimicrob. Agents Chemother.,1996, 40(10), 2356-2362.
90. Biavasco, F.; Vignaroli, C.; Lupidi, R.; Manso, E.; Facinelli, B.; Varaldo, P.E. In vitro antibacterial activity of LY333328, a newsemisynthetic glycopeptide. Antimicrob. Agents Chemother., 1997,41(10), 2165-2172.
91. Jones, R.N.; Barrett, M.S.; Erwin, M.E. In vitro activity and spectrumof LY333328, a novel glycopeptide derivative. Antimicrob.Agents Chemother., 1997, 41(2), 488-493.
92. Billot-Klein, D.; Blanot, D.; Gutmann, L.; Heijenoort, J.V. Association constants for the binding of vancomycin and teicoplanin toN-acetyl-D-alanyl-D-alanine and N-acetyl-D-alanyl-D-serine. Biochem.J., 1994, 304, 1021-1022.
93. Handwerger, S.; Pucci, M.J.; Volk, K.J.; Liu, J.; Lee, M.S. Vancomycin-resistant Leuconostoc mesenteroides and Lactobacillus caseisynthesize cytoplasmic peptidoglycan precursors that terminate inlactate. J. Bacteriol., 1994, 176(1), 260-264.
94. Nicas, T.I.; Mullen, D.L.; Flokowitsch, J.E.; Preston, D.A.; Snyder, N.J.; Zweifel, M.J.; Wilkie, S.C.; Rodriguez, M.J.; Thompson, R.C.; Cooper, R.D. Semisynthetic glycopeptide antibiotics derivedfrom LY264826 active against vancomycin-resistant enterococci.Antimicrob. Agents Chemother., 1996, 40(9), 2194-2199.
95. Biavasco, F.; Vignaroli, C.; Lupidi, R.; Manso, E.; Facinelli, B.; Varaldo, P.E. In vitro antibacterial activity of LY333328, a newsemisynthetic glycopeptide. Antimicrob. Agents Chemother., 1997,41(10), 2165-2172.
96. Crandon, J.; Nicolau, D.P. Oritavancin: a potential weapon in thebattle against serious Gram-positive pathogens. Future Microbiol.2008, 3(3), 251-263.
97. Nicas, T.I.; Mullen, D.L.; Flokowitsch, J.E.; Preston, D.A.; Snyder, N.J.; Stratford, R.E.; Cooper, R.D. Activities of the semisyntheticglycopeptide LY191145 against vancomycin-resistant enterococciand other gram-positive bacteria. Antimicrob. Agents Chemother.,1995, 39(11), 2585-2587.
98. Zeckel, M.L.; Preston, D.A.; Allen, B.S. In vitro activities of LY333328 and comparative agents against nosocomial gram positive pathogens collected in a 1997 global surveillance study. Antimicrob. Agents Chemother., 2000, 44(5), 1370-1374.
99. Malabarba, A.; Goldstein, B.P. Origin, structure, and activity invitro and in vivo of dalbavancin. J. Antimicrob. Chemother., 2005,55(Suppl. 2), S15-S20.
100. Pope, S.D.; Roecker, A.M. Dalbavancin: a novel lipoglycopeptide antibacterial. Pharmacotherapy, 2006, 26(7), 908-918.
101. Bailey, J.; Summers, K.M. Dalbavancin: a new lipoglycopeptideantibiotic. Am. J. Health Syst. Pharm., 2008, 65(7), 599-610.
102. Busse, K.H.; Oltrogge, K.M.; Oxencis, C.J.; Peppard, W.J. Dalbavancin:A review of its use in the treatment of Gram-positive infections. Clinical Medicine Insights: Therapeutics., 2010, (2), 7-13.
103. Biedenbach, D.J.; Bell, J.M.; Sader, H.S.; Turnidge, J.D.; Jones, R.N. Activities of dalbavancin against a worldwide collection of81,673 gram-positive bacterial isolates. Antimicrob. Agents Chemother.,2009, 53(3),1260-1263.
104. Biedenbach, D.J.; Jones, R.N. Multicenter evaluation of the in vitroactivity of dalbavancin tested against staphylococci and streptococciin 5 European countries: results from the DECIDE SurveillanceProgram (2007). Diagn. Microbiol. Infect. Dis., 2009, 64(2),177-184.
105. Gales, A.C.; Sader, H.S.; Jones, R.N. Antimicrobial activity of dalbavancin tested against Gram-positive clinical isolates from Latin American medical centres. Clin. Microbiol. Infect., 2005,11(2), 95-100.
106. Attwood, R.J.; LaPlante, K.L. Telavancin: a novel lipoglycopeptide anti microbial agent. Am. J. Health Syst. Pharm., 2007, 64(22),2335-2348.
107. Draghi, D.C.; Benton, B.M.; Krause, K.M.; Thornsberry, C.; Pillar, C.; Sahm, D.F. Comparative surveillance study of telavancin activityagainst recently collected gram-positive clinical isolates fromacross the United States. Antimicrob. Agents Chemother., 2008,52(7), 2383-2388.
108. Draghi, D.C.; Benton, B.M.; Krause, K.M.; Thornsberry, C.; Pillar, C.; Sahm, D.F. In vitro activity of telavancin against recent Grampositiveclinical isolates: results of the 2004-05 Prospective European Surveillance Initiative. J. Antimicrob. Chemother., 2008,62(1), 116-121.
109. Stryjewski, M.E.; Graham, D.R.; Wilson, S.E.; O'Riordan, W.; Young, D.; Lentnek, A.; Ross, D.P.; Fowler, V.G.; Hopkins, A.; Friedland, H.D.; Barriere, S.L.; Kitt, M.M.; Corey, G.R. Telavancinversus vancomycin for the treatment of complicated skin and skinstructureinfections caused by gram-positive organisms. Clin. Infect.Dis., 2008, 46(11), 1683-1693.
110. Ohlsen, K. Novel antibiotics for the treatment of Staphylococcusaureus. Expert. Rev. Clin. Pharmacol., 2009, 2(6), 661-672.
111. He, H. Mannopeptimycins, a novel class of glycopeptide antibioticsactive against gram-positive bacteria. Appl. Microbiol. Biotechnol.,2005, 67(4), 444-452.
112. Ruzin, A.; Singh, G.; Severin, A.; Yang, Y.; Dushin, R.G.; Sutherland, A.G.; Minnick, A.; Greenstein, M.; May, M.K.; Shlaes, D.M.; Bradford, P.A. Mechanism of action of the mannopeptimycins, anovel class of glycopeptide antibiotics active against vancomycinresistantgram-positive bacteria. Antimicrob. Agents. Chemother.,2004, 48(3), 728-738.
113. Singh, M.P.; Petersen, P.J.; Weiss, W.J.; Janso, J.E.; Luckman, S.W.; Lenoy, E.B.; Bradford, P.A.; Testa, R.T.; Greenstein, M. Mannopeptimycins, new cyclic glycopeptide antibiotics producedby Streptomyces hygroscopicus LL-AC98: antibacterial and mechanistic activities. Antimicrob. Agents Chemother., 2003,47(1), 62-69.
114. Weiss, W.J.; Murphy, T.; Lenoy, E.; Young, M. In vivo efficacyand pharmacokinetics of AC98-6446, a novel cyclic glycopeptide,in experimental infection models. Antimicrob. Agents. Chemother.,2004, 48(5), 1708-1712.
115. Lamb, S.S.; Patel, T.; Koteva, K.P.; Wright, G.D. Biosynthesis of sulfated glycopeptide antibiotics by using the sulfo transferase StaL.Chem. Biol., 2006, 13(2), 171-181.
116. Lancini, G.C.; Cavalleri, B. Glycopeptide Antibiotics of the Vancomycin Group. In: Biochemistry of peptide antibiotics; Kleinhauf,H.; Dohren, H.V., Eds., Walter de Gruyter. Berlin, 1990, pp. 159-178.
117. Pelzer, S.; Dziarnowski, A. Sulfation: a new biocombinatorial tool. Chem. Biol., 2006, 13(2), 113-114.